Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06857838

Myocardialbridge Bypass Graft Surgery Efficacy Verification

Myocardial Bridge Bypass Graft surgery is introduced to relieve the unmedical symptoms of patients with long-segment or deep myocardial bridge, clinical outcomes will be collected to verify the effectiveness of the surgery.

Recruiting

Interested in participating?

Request Info

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with myocardialbridge requiring drug therapy or surgical intervention.

Exclusion criteria

  • patients with myocardialbridge not requiring drug therapy or surgical intervention, or unwilling to be enrolled for any reason

Treatment and study plan

MBBG

Procedure

The patients with deep(depth>2mm) and long-segement(length>25mm) of myocardialbridge receiving myocardialbridge bypass graft surgery(MBBG),fulfilling the following criteria: 1.presenting with pectoris angina that cannot be effectively relieved by maximum guideline-directed drug therapy; 2. No atherosclerotic plaque or merely mild atherosclerotic stenosis is detected at the proximal or entry of the myocardialbridge confirmed by coronory artery angiography.

MB CABG

Procedure

The patients with deep(depth>2mm) and long-segement(length>25mm) of myocardialbridge receiving myocardialbridge bypass graft surgery(MBBG),fulfilling the following criteria: 1.presenting with pectoris angina that cannot be effectively relieved by maximum guideline-directed drug therapy; 2. The moderate-to-severe atherosclerotic stenosis is detected at the proximal or entry of the myocardialbridge confirmed by coronory artery angiography.

MB unroof

Procedure

The patients with superficial type(depth<2mm) and short-segement(length<25mm) of myocardial bridge will be allocated to receive myocardialbridge "unroof" surgery,when fulfilling the following criteria: 1.presenting with pectoris angina that cannot be effectively relieved by maximum guideline-directed drug therapy; 2. The MB was superficial and short confirmed by coronory artery CT angiography.

Primary outcomes

  1. All-Cause Mortality

    Time frame: Up to 240 months

  2. Rate of counduit patency

    Time frame: Up to 180 months

Study contacts

Contact information is provided by the study sponsor or research team.

Jinzhou Zhang, Doctorate

CONTACT

[email protected]

+86-029-68302464

Zhen Wang, Doctorate

CONTACT

[email protected]

+86-029-68302464

Sponsors and collaborators

Lead sponsor

Xi'an International Medical Center Hospital

Other

Registry information

Important dates

Study start
2020
Primary completion
2030
Study completion
2040
First posted
Mar 4, 2025
Registry last updated
Mar 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.